Rationale of statin therapy in septic patients

Current Vascular Pharmacology

Volumn 11, Issue 5, 2013, Pages 795-800

  Piechota, Mariusz ^a   Barylski, Marcin ^a   Hannam, Simon ^b   Piechota Urbańska, Magdalena ^c   Banach, Maciej ^c  

^a Military Medical Academy University Hospital in Lodz   (Poland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bacteremia; Infection; Management; Sepsis; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NITRIC OXIDE SYNTHASE; PRAVASTATIN; SIMVASTATIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTIFICIAL VENTILATION; BACTEREMIA; DISEASE ASSOCIATION; DRUG MEGADOSE; ENDOTOXEMIA; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNE RESPONSE; INFLAMMATION; INTENSIVE CARE; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; REVIEW; SEPSIS;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SEPSIS; SHOCK, SEPTIC;

EID: 84888112003     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311050018     Document Type: Review

References (72)

1. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-82.
2. Katsiki N, Mikhailidis DP, Banach M. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 2011; 29: 2493-4.
3. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
4. Pandey AS, Bissonnette S, Boukas S, Rampakakis E, Sampalis JS. Effectiveness and tolerability of ezetimibe co-administered with statins vs. statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. Arch Med Sci 2011; 7: 767-75.
5. Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr 2010; 50: 114-8.
6. Aydin U, Ugurlucan M, Gungor F, et al. Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology 2009; 60: 370-7.
7. Tycinska AM, Janica J, Mroczko B, et al. Hypotensive effect of atorvastatin in hypertensive patients: the association among flowmediated dilation, oxidative stress and endothelial dysfunction. Arch Med Sci 2011; 7: 955-62.
8. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmaski R, Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 2006; 48: 143-7.
9. Goodin J, Manrique C, Dulohery M, Sampson J, Saettele M, Dabbagh O. Effect of statins on the clinical outcomes of patients with sepsis. Anaesth Intensive Care 2011; 39: 1051-5.
10. Piechota M, Banach M, Irzmanski R, et al. Plasma endothelin-1 levels in septic patients. J Intensive Care Med 2007; 22: 232-9.
11. Leung S, Pokharel R, Gong MN. Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Crit Care Med 2012; 40: 1064-71.
12. Bone RC, Balk RA, Cerra FB, et al. ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136(5 Suppl): e28.
13. Levy MM, Fink MP, Marshall JC, et al.; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6.
14. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United State: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
15. Padkin AM, Goldfrad CM, Brady ARM, Young DD, Black NM, Rowan KD. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003; 31: 2332-8.
16. Piechota M, Barylski M, Hannam S, Mikhailidis DP, Rysz J, Banach M. Natriuretic peptides in septic patients. Curr Med Chem 2009; 16: 4020-31.
17. Piechota M, Banach M, Irzmaski R, et al. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. Cell Mol Biol Lett 2007; 12: 162-75.
18. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol 2007; 28: 88-98.
19. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-70.
20. Beotowski J, Wójcicka G, Jamroz-Winiewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 2009; 4: 209-28.
21. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002; 23: 482-6.
22. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Antiinflammatory and immunomodulatory effects of statins. Kidney Int 2003; 63: 12-23.
23. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackman DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007; 7: 358-68.
24. Martin CP, Talbert RL, Burgess DS, Peters JI. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 2007; 27: 20-6.
25. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
26. Weitz-Schmidt G. Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance. Endothelium 2003; 10: 43-7.
27. Zingarelli B. Nuclear factor-kappaB. Crit Care Med 2005; 33: S414-6.
28. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61: 774-85.
29. Kronmann L, Hatfield C, Kronmann K. Statin therapy: not just used to lower cholesterol? Crit Care Nurs Q 2007, 30: 154-60.
30. Iijima K, Ouchi Y. Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment. Clin Calcium 2010; 20: 1719-28.
31. Bu DX, Griffin G, Lichtman AH. Mechanisms for the antiinflammatory effects of statins. Curr Opin Lipidol 2011; 22: 165-70.
32. Peña JM, Macfadyen J, Glynn RJ, Ridker PM. High-sensitivity Creactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33: 531-7.
33. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
34. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Longterm effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.
35. Ridker PM, Cannon CP, Morrow D, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
36. Bruegel M, Teupser D, Haffner I, Mueller M, Thiery J. Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin Exp Pharmacol Physiol 2006; 33: 1144-9.
37. Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002; 160: 49-58.
38. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5.
39. Park KW, Hwang KK, Cho HJ, et al. Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Clin Chim Acta 2008; 388: 156-66.
40. Inoue K, Takano H, Yanagisawa R, Sakurai M, Yoshikawa T. Statin, inflammation, and sepsis. Chest 2004; 125: 2365.
41. Giusti-Paiva A, Martinez MR, Felix JV, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 2004; 21: 271-5.
42. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004; 110: 3349-54.
43. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006; 32: 75-9.
44. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352-7.
45. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-67.
46. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006; 34: 1080-6.
47. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006; 333: 999-1001.
48. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2006; 32: 160-4.
49. Calisto KL, Carvalho Bde M, Ropelle ER, et al. Atorvastatin improves survival in septic rats: effect on tissue inflammatory pathway and on insulin signaling. PLoS One 2010; 5: e14232.
50. Araújo-Filho I, Jácome DT, Rêgo AC, Azevedo IM, Egito ES, Medeiros AC. Effect of the simvastatin in abdominal sepsis of diabetic rats. Rev Col Bras Cir 2010; 37: 39-44.
51. McGown CC, Brown NJ, Hellewell PG, Reilly CS, Brookes ZL. Beneficial microvascular and anti-inflammatory effects of pravastatin during sepsis involve nitric oxide synthase III. Br J Anaesth 2010; 104: 183-90.
52. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-5.
53. Al Harbi SA, Tamim HM, Arabi YM. Association Between Statin Therapy and Outcomes in Critically Ill Patients: a Nested Cohort Study. BMC Clin Pharmacol 2011; 11: 12.
54. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009; 29: 621-30.
55. Mortensen EM, Restrepo MI, Copeland LA, et al. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007; 27: 1619-26.
56. Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; 39: 1871-8.
57. Fuller BM, Gajera M, Schorr C, Gerber D, Dellinger RP, Zanotti S. The association of prior statin use in septic shock treated with early goal directed therapy. Eur J Emerg Med 2012; 19: 226-30.
58. Mekontso Dessap A, Ouanes I, Rana N, et al. Effects of discontinuing or continuing ongoing statin therapy in severe sepsis and septic shock: a retrospective cohort study. Crit Care 2011; 15: R171.
59. Yang KC, Chien JY, Tseng WK, Hsueh PR, Yu CJ, Wu CC. Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 2007; 25: 494-501.
60. von Haehling S, Schefold JC, Springer J, Anker SD. The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond. Heart Fail Clin 2008; 4: 141-51.
61. Woerndle RH, Maxwell DL. Statins and sepsis: good bullet, disappearing target. J Am Osteopath Assoc 2008; 108: 486-90.
62. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-9.
63. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942 23-30.
64. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
65. Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischaemia and reperfusion in the rat. Med Sci Monit 2003; 9: BR195-9.
66. McGown CC, Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth 2007; 98: 163-75.
67. Gao F, Linhartova L, Johnston AM, Johnston AM, Thickett DR. Statins and sepsis. Br J Anaesth 2008; 100: 288-98.
68. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis 2006; 6: 242-8.
69. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 2011; 7: 1000-12.
70. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 2010; 11: 2665-74.
71. Makris GC, Geroulakos G, Makris MC, Mikhailidis DP, Falagas ME. The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective. Expert Opin Investig Drugs 2010; 19: 809-14.
72. Paraskevas KI, Koupidis S, Gentimi F, Tzovaras AA. Statin discontinuation: counterbalancing the benefits with the potential risks. Arch Med Sci 2011; 7: 1076-7.